Trevi Therapeutics reports Q3 2022 net loss of $8.3M; cash at $126M

Trevi Therapeutics, Inc.

2022-Q3 EPS reported -$0.44

Net loss of $8.3M in Q3 2022 vs. $7.3M in Q3 2021; R&D expenses rose to $5.8M.
Cash, cash equivalents, and investments totaled $126M as of Sept 30, 2022.
Phase 2 CANAL trial for chronic cough in IPF met primary endpoint with 75.1% reduction in cough frequency (placebo-adjusted 52.5%, p<0.0001).
Phase 2b/3 PRISM trial for prurigo nodularis open-label extension ongoing; end-of-phase 2 FDA meeting planned Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Trevi Therapeutics, Inc. reported quarter ended September 30, 2022 results: net income net loss of $8.3 million.

Period: quarter ended September 30, 2022
Net income: net loss of $8.3 million
Result: reported results

Exact text from the filing

For the third quarter of 2022, the Company reported a net loss of $8.3 million, compared to a net loss of $7.3 million in the same period in 2021.

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-037382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.